報價延遲最少15分鐘:2026/04/16 14:28 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.145 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.74/-0.33
|
|
企業價值
892.74M
|
| 資產負債 |
|
每股賬面淨值
1.15
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
84.28M
|
|
每股收益
0.00
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. |
